Caption Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Caption Management’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-101,500	Closed	-$610K	–	1724
2022 Q4	$610K	Buy	+101,500	New	+$554K	0.01%	876
2022 Q3	–	Sell	-60,700	Closed	-$362K	–	1981
2022 Q2	$362K	Buy	+60,700	New	+$311K	0.01%	1140

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Caption Management's CTIC Position: Q2 2023 in Review

Caption Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 100,000 shares — an estimated $420K sold.

Caption Management first reported a position in CTIC in Q2 2022 and held it in 3 quarters. The position peaked at $420K in Q1 2023. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Caption Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Caption Management sold 100,000 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $420K.
Caption Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2022 and held it in 3 quarters.
Caption Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $420K in Q1 2023.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Caption Management's 13F filing for Q2 2023, filed 14 Aug 2023.